| Dr Fuad Zayed, MD | |
|
3012 E Main Ave Ste F, Alton, TX 78573-0908 | |
| (956) 432-0150 | |
| (956) 432-0154 |
| Full Name | Dr Fuad Zayed |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 34 Years |
| Location | 3012 E Main Ave Ste F, Alton, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356342190 | NPI | - | NPPES |
| 173373502 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | L9571 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors Hospital At Renaissance | Edinburg, TX | Hospital |
| Entity Name | Fuad Zayed,md,pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619912433 PECOS PAC ID: 9830195106 Enrollment ID: O20061010000141 |
News Archive
A study by Massachusetts General Hospital researchers - collaborating with a team at the Karolinska Institutet in Sweden - has documented for the first time widespread inflammation in the brains of patients with the poorly understood condition called fibromyalgia.
The RAF protein could be a therapeutical target to treat the tumor growth in regulated pathways by the p38 protein, according to a new study published in the journal Scientific Reports by a team of experts of the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Institute for Biomedical Research.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.
Hospira announced today that the EC has approved Nivestim™ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.
› Verified 7 days ago
| Entity Name | Renaissance Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467633867 PECOS PAC ID: 1153409867 Enrollment ID: O20080422000326 |
News Archive
A study by Massachusetts General Hospital researchers - collaborating with a team at the Karolinska Institutet in Sweden - has documented for the first time widespread inflammation in the brains of patients with the poorly understood condition called fibromyalgia.
The RAF protein could be a therapeutical target to treat the tumor growth in regulated pathways by the p38 protein, according to a new study published in the journal Scientific Reports by a team of experts of the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Institute for Biomedical Research.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.
Hospira announced today that the EC has approved Nivestim™ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.
› Verified 7 days ago
| Entity Name | Dilydis Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821317843 PECOS PAC ID: 5799972758 Enrollment ID: O20101203000483 |
News Archive
A study by Massachusetts General Hospital researchers - collaborating with a team at the Karolinska Institutet in Sweden - has documented for the first time widespread inflammation in the brains of patients with the poorly understood condition called fibromyalgia.
The RAF protein could be a therapeutical target to treat the tumor growth in regulated pathways by the p38 protein, according to a new study published in the journal Scientific Reports by a team of experts of the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Institute for Biomedical Research.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.
Hospira announced today that the EC has approved Nivestim™ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Fuad Zayed, MD Po Box 6085, Mcallen, TX 78502-6085 Ph: (956) 432-0150 | Dr Fuad Zayed, MD 3012 E Main Ave Ste F, Alton, TX 78573-0908 Ph: (956) 432-0150 |
News Archive
A study by Massachusetts General Hospital researchers - collaborating with a team at the Karolinska Institutet in Sweden - has documented for the first time widespread inflammation in the brains of patients with the poorly understood condition called fibromyalgia.
The RAF protein could be a therapeutical target to treat the tumor growth in regulated pathways by the p38 protein, according to a new study published in the journal Scientific Reports by a team of experts of the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Institute for Biomedical Research.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.
Hospira announced today that the EC has approved Nivestim™ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.
› Verified 7 days ago
Anna Atencio, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 306 E Main Ave, Suite 5 & 6, Alton, TX 78573 Phone: 956-424-7655 Fax: 956-424-7049 |